Neuren Pharmaceuticals Ltd has released a press release.
First subject commences Neurens Rett syndrome Phase 2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Neuren awarded Rett Syndrome trial grant
- Trial of Second Neuren Drug Motiva to be Initiated
- Neuren Starts Phase II Trial of NNZ2566
- Grant funding for TFF oncology program
- Cato strategic partnership and appoints US CMO
Later from Neuren Pharmaceuticals
- Results of Phase 2 trial in moderate to severe TBI
- Grant of new patent for Autism Spectrum Disorders
- Neuren presents at Rettsyndrome.org 2016 Research Symposium
- Neuren expands Phase 2 Rett syndrome pediatric trial
- Neuren receives $0.9m from exercise of last expiring options
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals